These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 37006677)

  • 1. Development of synthetic, self-adjuvanting, and self-assembling anticancer vaccines based on a minimal saponin adjuvant and the tumor-associated MUC1 antigen.
    Pifferi C; Aguinagalde L; Ruiz-de-Angulo A; Sacristán N; Baschirotto PT; Poveda A; Jiménez-Barbero J; Anguita J; Fernández-Tejada A
    Chem Sci; 2023 Mar; 14(13):3501-3513. PubMed ID: 37006677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates.
    Kim SK; Ragupathi G; Cappello S; Kagan E; Livingston PO
    Vaccine; 2000 Oct; 19(4-5):530-7. PubMed ID: 11027818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic self-adjuvanting glycopeptide cancer vaccines.
    McDonald DM; Byrne SN; Payne RJ
    Front Chem; 2015; 3():60. PubMed ID: 26557640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic self-adjuvanted multivalent Mucin 1 (MUC1) glycopeptide vaccines with improved in vivo antitumor efficacy.
    Zhou Y; Li X; Guo Y; Wu Y; Yin L; Tu L; Hong S; Cai H; Ding F
    MedComm (2020); 2024 Feb; 5(2):e484. PubMed ID: 38344400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A totally synthetic, self-assembling, adjuvant-free MUC1 glycopeptide vaccine for cancer therapy.
    Huang ZH; Shi L; Ma JW; Sun ZY; Cai H; Chen YX; Zhao YF; Li YM
    J Am Chem Soc; 2012 May; 134(21):8730-3. PubMed ID: 22587010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modular platforms for the assembly of self-adjuvanting lipopeptide-based vaccines for use in an out-bred population.
    Zeng W; Horrocks KJ; Tan ACL; Wong CY; Chua BY; Jackson DC
    Vaccine; 2020 Jan; 38(3):597-607. PubMed ID: 31740096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine.
    Lakshminarayanan V; Thompson P; Wolfert MA; Buskas T; Bradley JM; Pathangey LB; Madsen CS; Cohen PA; Gendler SJ; Boons GJ
    Proc Natl Acad Sci U S A; 2012 Jan; 109(1):261-6. PubMed ID: 22171012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and immunological evaluation of self-adjuvanting MUC1-macrophage activating lipopeptide 2 conjugate vaccine candidates.
    McDonald DM; Wilkinson BL; Corcilius L; Thaysen-Andersen M; Byrne SN; Payne RJ
    Chem Commun (Camb); 2014 Sep; 50(71):10273-6. PubMed ID: 25056269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fully Synthetic Invariant NKT Cell-Dependent Self-Adjuvanting Antitumor Vaccines Eliciting Potent Immune Response in Mice.
    Chen PG; Hu HG; Sun ZY; Li QQ; Zhang BD; Wu JJ; Li WH; Zhao YF; Chen YX; Li YM
    Mol Pharm; 2020 Feb; 17(2):417-425. PubMed ID: 31841011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and immunological evaluation of self-assembling and self-adjuvanting tricomponent glycopeptide cancer-vaccine candidates.
    Wilkinson BL; Day S; Chapman R; Perrier S; Apostolopoulos V; Payne RJ
    Chemistry; 2012 Dec; 18(51):16540-8. PubMed ID: 23090901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological Evaluation of Recent MUC1 Glycopeptide Cancer Vaccines.
    Hossain MK; Wall KA
    Vaccines (Basel); 2016 Jul; 4(3):. PubMed ID: 27472370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First self-adjuvant multicomponent potential vaccine candidates by tethering of four or eight MUC1 antigenic immunodominant PDTRP units on a calixarene platform: synthesis and biological evaluation.
    Geraci C; Consoli GM; Granata G; Galante E; Palmigiano A; Pappalardo M; Di Puma SD; Spadaro A
    Bioconjug Chem; 2013 Oct; 24(10):1710-20. PubMed ID: 24041198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Precise immunological evaluation rationalizes the design of a self-adjuvanting vaccine composed of glycan antigen, TLR1/2 ligand, and T-helper cell epitope.
    Chang TC; Manabe Y; Ito K; Yamamoto R; Kabayama K; Ohshima S; Kametani Y; Fujimoto Y; Lin CC; Fukase K
    RSC Adv; 2022 Jun; 12(29):18985-18993. PubMed ID: 35873332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis of a Self-Adjuvanting MUC1 Vaccine via Diselenide-Selenoester Ligation-Deselenization.
    McDonald DM; Hanna CC; Ashhurst AS; Corcilius L; Byrne SN; Payne RJ
    ACS Chem Biol; 2018 Dec; 13(12):3279-3285. PubMed ID: 30359529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in self-adjuvanting glycoconjugate vaccines.
    Manabe Y; Chang TC; Fukase K
    Drug Discov Today Technol; 2020 Dec; 37():61-71. PubMed ID: 34895656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MUC1 Glycopeptide Vaccine Modified with a GalNAc Glycocluster Targets the Macrophage Galactose C-type Lectin on Dendritic Cells to Elicit an Improved Humoral Response.
    Gabba A; Attariya R; Behren S; Pett C; van der Horst JC; Yurugi H; Yu J; Urschbach M; Sabin J; Birrane G; Schmitt E; van Vliet SJ; Besenius P; Westerlind U; Murphy PV
    J Am Chem Soc; 2023 Jun; 145(24):13027-13037. PubMed ID: 37279388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alum Adjuvant and Built-in TLR7 Agonist Synergistically Enhance Anti-MUC1 Immune Responses for Cancer Vaccine.
    Zhou SH; Li YT; Zhang RY; Liu YL; You ZW; Bian MM; Wen Y; Wang J; Du JJ; Guo J
    Front Immunol; 2022; 13():857779. PubMed ID: 35371101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rational Design of T-Cell- and B-Cell-Based Therapeutic Cancer Vaccines.
    Li WH; Su JY; Li YM
    Acc Chem Res; 2022 Sep; 55(18):2660-2671. PubMed ID: 36048514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonist.
    Abdel-Aal AB; Lakshminarayanan V; Thompson P; Supekar N; Bradley JM; Wolfert MA; Cohen PA; Gendler SJ; Boons GJ
    Chembiochem; 2014 Jul; 15(10):1508-13. PubMed ID: 24890740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Innovative Vaccine Strategy: Self-Adjuvanting Conjugate Vaccines.
    Manabe Y; Fukase K
    Methods Mol Biol; 2023; 2613():55-72. PubMed ID: 36587070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.